Novo Nordisk has submitted an approval application for a new diabetes pill to the FDA.
Like other diabetes treatments, the new drug is part of a class of blockbuster GLP-1 diabetes medications. But other treatments have to be administered via injected — and for the first time, Novo Nordisk’s drug would offer diabetes patients a once-daily pill.
Novo Nordisk is banking on the approval of its new treatment to reinvigorate its diabetes portfolio, which will face new generics competition in a few years.
The treatment received a priority review voucher from the FDA, which could shorten the review time to six months.
Read the full Reuters report.